| BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE | Takeda | ||
| 90MG;8MG: Tablet, Extended Release |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
Less Than 5
|
||
| None | None | ||
| CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese or over weight adults. | |||
|
Yes
| |||
| Contrave | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ******* | *** ** ** | *** ** ** | **** ** *** *, **** | **** ** *** *, **** | **** ** *** *, **** | **** ** *** *, **** | **** ** ** | *** ********* | **** ** *** **, **** | *** ********* | *** ********* | *** ********* |
| ************ *** ******* *** ****** **** ** ** **** ******* *********** | ******* *** ************* ****** **** *********** | ************ *** ********* ****** **** | ************ *** ********* ****** **** | ******* ************** ************ | ******* ************** ************ | ******* *** ************* ****** **** *********** | ************ *** ******* *** ********** ******* *********** | ********* ******* *********** ** ********** | ********* ******* *********** ** ********** | ******* *** ************* ****** **** *********** | ******* ** ********* ****** **** ******* ** ******** **** ***** ********** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ******* | *** \ ** | *** *, **** | *** ** ** ** ******* '***, '*** *** **** ** ** ** ****** '*** | ********* ******** | ***** *** **** |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|